Stock Update: GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

[GlobeNewswire] GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, provided the following details regarding its upcoming Research and Development Day.The program will provide an update on GW's product pipeline and is expected to include presentations on the science and application of cannabinoids, updated data from the Epidiolex(R) epilepsy expanded access program, and a review of current pipeline programs including initial data from GW's ulcerative colitis Phase 2a clinical trial.Stock PerformanceTaking a look at the company’s recent performance, GW Pharmaceuticals PLC- ADR (GWPH) reported third quarter earnings for fiscal 2014 on August 6^th. The company reported actual earnings per share of $0.06 against the consensus Street estimate of $-1.08. This represents year over year growth of 200%. GW Pharmaceuticals posted revenue of $13 million against estimates of $12.8 million.GW Pharmaceuticals is currently valued at $1.31 billion and closed the last trading session at $71.99. The stock has a 50-day moving average of $88.73 and a 200-day moving average of $78.01.

Is this a Buying Opportunity?There are currently seven analysts that we track that cover the stock. Of those seven, six have a Buy rating and one has a hold rating. On a consensus basis this yields a score of 2.86 and a Buy. The combined price objective of these covering analysts is $91.43, which represents a 13.08% difference to the last closing price.The most recent analyst activity consisted of Peel Hunt downgrading their Buy stance on the company. On the date of the report, the stock closed at $84.88.Another research firm weighing in recently was Piper Jaffray who boosted their rating on the stock. On June 6^th Piper Jaffray boosted their price target on the stock from $97 to $147, or a 88.2% upside to the current price. On the day of the report, GWPH shares closed at $71.99.Company ProfileGW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. The company operates through three segments: Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia